Etoposide-incorporated tripalmitin nanoparticles with different surface charge: Formulation, characterization, radiolabeling, and biodistribution studies

AAPS Journal

Volumn 6, Issue 3, 2004, Pages

  Reddy, Lakkireddy Harivardhan ^a   Sharma, Rakesh Kumar ^b   Chuttani, Krishna ^b   Mishra, Anil Kumar ^b   Murthy, Rayasa Ramachandra ^a  

^a M S UNIVERSITY OF BARODA   (India)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

Biodistribution; Etoposide; Long circulating nanoparticles; Radiolabeling; Technetium 99m; Tripalmitin

Indexed keywords

CYSTEINE; ETOPOSIDE; NANOPARTICLE; PENTETIC ACID; TECHNETIUM 99M; TRIPALMITIN; ANTINEOPLASTIC AGENT; DRUG CARRIER; NANOMATERIAL; TECHNETIUM; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CHEMICAL PROCEDURES; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG STABILITY; DRUG TARGETING; DRUG UPTAKE; EMULSION; FEMALE; IN VITRO STUDY; ISOTOPE LABELING; LIVER; MALE; MOUSE; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PROVOCATION TEST; RETICULOENDOTHELIAL SYSTEM; SCANNING ELECTRON MICROSCOPY; SPLEEN; SPRAY DRYING; SURFACE CHARGE; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; RAT; SPRAGUE DAWLEY RAT; SURFACE PROPERTY; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG CARRIERS; ETOPOSIDE; FEMALE; ISOTOPE LABELING; MALE; MICE; MICE, INBRED BALB C; NANOSTRUCTURES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; SURFACE PROPERTIES; TECHNETIUM; TISSUE DISTRIBUTION; TRIGLYCERIDES;

EID: 33646648428     PISSN: 15221059     EISSN: 15221059     Source Type: Journal    
DOI: 10.1208/aapsj060323     Document Type: Article

References (43)

1. Muller RH, Olbrich C. Solid lipid nanoparticles: Phagocytic uptake, in vitro cytotoxicity and in vitro biodegradation. Drugs Made Ger. 1999;142:49-53.
2. Lim SJ, Kim CK. Formulation parameters determining the physicochemical characteristics of solid lipid nanoparticles loaded with all-trans retinoic acid. Int J Pharm. 2002;243:135-146.
3. Freitas C, Muller RH. Spray-drying of solid lipid nanoparticles (SLN™). Eur J Pharm Biopharm. 1998;46:145-151.
4. Magenheim B, Levy MY, Benita S. A new in vitro technique for evaluation of drug release profile from colloidal carriers ultrafiltration technique at low pressure. Int J Pharm. 1993;94:115-123.
5. Muller RH, Ruhl D, Runge S, Schulze-Foster K, Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res. 1997;14:458-462.
6. zur Muhlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-Drug release and release mechanism. Eur J Pharm Biopharm. 1998;45:149-155.
7. Muller RH, Maassen S, Weyhers H, Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanopartictes (SLN) sterically stabilized with Poloxamine 908 and Poloxamer 407. J Drug Target. 1996;4:161-170.
8. Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization. J Microencapsul. 1999;16:205-213.
9. Unruh T, Bunjes H, Westesen K, Koch MHJ. Investigations on the melting behaviour of triglyceride nanoparticles. Colloid Polym Sci. 2001;279:398-403.
10. Cavalli R, Caputo O, Carlotti ME, Trotta M, Scarnecchia C, Gasco MR. Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int J Pharm. 1997;148:47-54.
11. Siekmann B, Westesen S. Thermoanalysis of the recrystallization process of melt-homogenized glyceride nanoparticles. Colloids Surf B Biointerfaces. 1994;3:159-175.
12. Westesen K, Bunjes H, Koch MHJ. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release. 1997;48:221-236.
13. Bunjes H, Drechsler M, Koch MHJ, Westesen K. Incorporation of the model drug Ubidecarenone into the solid lipid nanoparticles. Pharm Res. 2001;18:287-293.
14. Bunjes H, Koch MHJ, Westesen K. Effect of surfactants on the crystallization and polymorphism of lipid nanopartictes. Prog Colloid Polym Sci. 2002;121:7-10.
15. Bunjes H, Koch MHJ, Westesen K. Influence of emulsifiers on the crystallization of solid lipid nanoparticles. J Pharm Sci. 2003;92:1509-1520.
16. Bunjes H, Koch MHJ, Westesen K. Effect of particle size on colloidal solid triglycerides. Langmuir. 2000;16:5234-5241.
17. Mehnert W, Mader K. Solid lipid nanoparticles-production, characterization and applications. Adv Drug Del Rev. 2001;47:165-196.
18. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161-177.
19. Yang S, Zhu J, Lu Y, Liang B, Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res. 1999;16:751-757.
20. Penkler L, Muller RH, Runge SA, Ravelli V. Pharmaceutical cyclosporine formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation. WO 99/56733. 1999.
21. Zara GP, Cavalli R, Fundaro A, Bargoin A, Caputo O, Gasco MR. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharm Res. 1999;40:281-286.
22. Jaeghere ED, Doelker E, Gurny R. Nanoparticles. In: Mathiowitz E, ed. Encyclopedia of Controlled Drug Delivery. Vol 2. New York, NY: John Wiley; 1999:641-664.
23. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta. 1992;1113:171-199.
24. Senior JH. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst. 1987;3:123-193.
25. 99mTc-labeled liposome encapsulated cyclosporine. J Drug Target. 2003;11:187-196.
26. Chamberlain M. Recurrent brainstem gliomas treated with oral VP-16. Neuro-oncol. 1993;15:133-139.
27. Ashley D, Meier L, Kerby T, et al. Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol. 1996;14:1922-1927.
28. Subramanian NN, Arulsudar N, Chuttani K, Mishra P, Sharma RK, Murthy RSR. Radiolabeling, biodistribution and tumor imaging of stealth liposomes containing methotrexate. J Alasbimn. 2003;6(22):Article 6.
29. Arulsudar N, Subramanian N, Mishra P, Chuttani K, Sharma RK, Murthy RSR. Preparation, characterization and biodistribution of Technetium-99m-labeled leuprolide acetate-loaded liposomes in Ehrlich Ascites tumor bearing mice. AAPS PharmSci. 2004;6:E5.
30. 99mTc] technetium labeled liposomes in normal and tumor bearing rats. Biochem Soc Trans. 1977;5:290-291.
31. Theobald AE. Theory and practice. In: Sampson CB, ed. Textbook of Radiopharmacy. New York., NY: Gordon and Breach; 1990:127-129.
32. 99mTc-labeled 2-Iminothiolane modified antibodies and CITC-DTPA immunoconjugates of anti-EGF-receptor antibodies. Methods Find Exp Clin Pharmacol. 2002;24:653-660.
33. Siekmann B, Westesen K. Submicron-sized parenteral carrier systems based on solid lipids. Pharm Pharmacol Lett. 1992;1:123-126.
34. Westesen K, Siekmann B, Koch MHJ. Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction. Int J Pharm. 1993;93:189-199.
35. Westesen K, Siekmann B. Investigations on the gel formation of phospholipids stabilized solid lipid nanoparticles. Int J Pharm. 1997;151:35-45.
36. Siekmann B, Westesen K. Melt-homogenized solid lipid nanoparticles stabilized by the nonionic surfactant tyloxapol. I. Preparation and particle size determination. Pharm Pharmacol Lett. 1994;3:194-197.
37. Aoki H, Sun C, Fuji K, Miyajima K. Disposition kinetics of liposomes modified with synthetic aminoglycolipids in rats. Int J Pharm. 1995;115:183-191.
38. 99mTc-DTPA in rats. Ind J Pharmacol. 1998;30:199-202.
39. Levchenko et al. Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating. Int J Pharm. 2002;240:95-102.
40. Sengupta S. Tyagi P, Velpandian T, Gupta YK, Gupta SK. Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies. Pharmacol Res. 2000;42:459-464.
41. Yu HY, Lin CY. Uptake of charged liposomes by the rat liver. J Formos Med Assoc. 1997;96:409-413.
42. Hernandez-Caselles T, Villalain J, Gomez-Fernandez JC. Influence of liposome charge and composition on their interaction with human blood serum proteins. Mol Cell Biochem. 1993;120:119-126.
43. Duncan R. Polymer conjugates for tumor targeting and intracytoplasmic delivery. The EPR effect as a common gateway? Pharm Sci Tech Today. 1992;2:441-449.